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Introduction: We report outcomes for the combined cohort of
patients ages 80 or older from two chemotherapy trials in advanced
non-small cell lung cancer (NSCLC) conducted by the Southwest
Oncology Group (S0027) and an investigator-initiated trial (LUN 6).
Methods: Patients with chemotherapy-naı¨ve, stage IIIB/IV NSCLC,
ages 70 years or older with a performance status (PS) of 0 or 1, or
patients of any age with PS 2, were eligible. Treatment in the S0027
study was 25 mg/m2 of vinorelbine on days 1 and 8, every 21 days
for three cycles, and then 35 mg/m2 of docetaxel on days 1, 8, and
15, every 28 days for three cycles. Treatment in the LUN 6 study
was 30 mg/m2 of docetaxel on days 1, 8, and 15, every 28 days, or
75 mg/m2 every 21 days. Of the 228 patients treated, 49 (21.5%; 26
in LUN 6 and 23 in S0027) were ages 80 years or older. Analysis of
outcome was conducted in the 80-and-older group and was com-
pared with the under-80 cohort from S0027.
Results: Among patients with measurable disease, disease-control
rates (partial response  stable disease) were 54% (n  48) and
46% (n 89) in the 80-and-older and under-80 groups, respectively.
Median survival was 7 and 11 months in PS 0/1 patients in the
80-and-older and under-80 groups, respectively. Median survival
was 4 and 5 months in PS 2 patients in the 80-and-older and
under-80 groups, respectively. Treatment was well tolerated. Five
treatment-related deaths were noted: two (4%) and three (3.4%) in
the 80-or-younger and the under-80 groups, respectively.
Conclusions: These chemotherapy regimens were associated with
an encouraging disease-control rate (54%) in patients 80 years or
older with advanced NSCLC, with good tolerance. Selected octo-
genarians with advanced NSCLC may benefit from single-agent
chemotherapy.
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Lung cancer is the leading cause of cancer mortality in bothmen and women. It is projected that nearly 163,000
individuals will die from lung cancer in the United States in
2006.1 Risk of lung cancer clearly increases with advancing
age. Given the changing demographics of Western popula-
tions, the proportion of lung cancer patients older than 65
years has increased progressively in recent years. The latest
data from the U.S. Surveillance, Epidemiology, and End
Results program indicate that more than two of every three
lung cancer patients are more than 65 years old.2 In addition,
the proportion of patients ages 75 years or older has increased
to 35%, and the median age of newly diagnosed patients with
lung cancer in the United States is now 70 years.2
Despite the high proportion of older patients with lung
cancer, until relatively recently, there has been a paucity of
information from clinical trials to guide patient management
in this population. Analyses of trials sponsored by the Na-
tional Cancer Institute have documented the disproportion-
ately low representation of older patients in most disease
sites, including lung cancer.3,4 Retrospective analyses con-
ducted on the subset of patients older than 70 years in a
number of phase III trials in advanced non-small cell lung
cancer (NSCLC) have suggested that platinum-based doublet
therapy may be an appropriate option for fit elderly pa-
tients.5–9 In addition, a number of elderly-specific prospective
trials have clearly established the efficacy of single-agent
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chemotherapy in patients ages 70 years or older with ad-
vanced NSCLC.10–12
Despite the value of the emerging database on the use
of chemotherapy in elderly patients with NSCLC, virtually no
information is currently available to guide treatment deci-
sions for the growing group of patients ages 80 years or older.
This group of “very old” patients is rapidly growing in
numbers, accounting for more than 20% of all deaths from
lung cancer in the United States in 2006.1 Given the absence
of prospective data on the outcome of chemotherapy treat-
ment in “very old” NSCLC patients, we conducted an anal-
ysis of treatment outcomes in patients ages 80 years or older
from two trials conducted by the Southwest Oncology Group
(S0027), and a multicenter investigator-initiated trial (LUN
6). Both trials had similar eligibility requirements (patients
older than 70 years with advanced NSCLC and/or with a
performance status [PS] of 2) and single-agent treatment
regimens, which encouraged the inclusion of patients ages 80
years or older. Reports on the complete study populations
from each of these studies have been reported previously.13,14
This manuscript details treatment outcomes for the proportion
of patients at least 80 years old compared with the cohort of
patients under age 80 from S0027.
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically or cyto-
logically documented stage IIIB (LUN 6: any; S0027: pleural
effusion only) or stage IV NSCLC. Patients ages 70 years or
older with PS of 0/1, or those of any age with PS 2, were
eligible. All patients were required to be 18 years of age or
older and to have acceptable hepatic, cardiac, and hemato-
logic function. Patients on S0027 were required to have
measurable or evaluable disease documented by computed
tomography, magnetic resonance imaging, x-ray, physical
exam, or nuclear exam. Patients with brain metastases were
excluded from S0027. They were allowed on LUN 6 if the
brain metastases were controlled. No prior systemic chemo-
therapy, biologic therapy, or radiation therapy for NSCLC
was allowed. Patients with symptomatic neuropathy of grade
2 or higher, or active pregnancy, were ineligible for inclusion
in the trial. The study was approved by the institutional
review boards of the respective institutions, and all patients
gave written informed consent.
Treatment Plan
S0027
Patients received 25 mg/m2 of vinorelbine intrave-
nously on day 1 and day 8 of a 21-day cycle for three cycles,
followed by 35 mg/m2 of docetaxel on days 1, 8, and 15 of a
28-day cycle for three cycles. Patients with early evidence of
disease progression before receiving all three cycles of vi-
norelbine were immediately sequenced to docetaxel. Treat-
ment was limited to six total cycles of therapy. Treatment at
the time of disease recurrence or progression after six cycles
were left to the discretion of each treating physician.
LUN 6
Patients were randomized to receive 75 mg/m2 of
docetaxel intravenously on day 1 of a 21-day cycle or 30
mg/m2 of docetaxel intravenously on days 1, 8, and 15 of a
28-day cycle. Treatment was continued until there was evi-
dence of progressive disease or unacceptable side effects.
Response and Toxicity Criteria
Response and progression on both protocols were de-
termined using the Response Evaluation Criteria in Solid
Tumors criteria.15 Adverse events were graded using the
National Cancer Institute Common Toxicity Criteria 2.0.16
Criteria for removal of patients from the study included
completion of six cycles of chemotherapy (S0027), progres-
sion of disease or unacceptable toxicity as determined by the
treating physician in consultation with the study coordinator,
or patient refusal.
Statistical Considerations
S0027
The statistical design of S0027 has been outlined pre-
viously in the full study report.13
LUN 6
The primary objective of this trial was to assess the
incidence of selected toxicities, with the hypothesis that the
weekly schedule would be better tolerated. Assuming that
36% of patients on the schedule of every 3 weeks would
experience at least one grade 3 or 4 toxicity, and assuming an
18% incidence rate of grade 3 or 4 toxicity for patients on the
weekly schedule, a total of 106 patients for each treatment
group would be needed to detect a treatment difference with
80% power at the 95% significance level.
RESULTS
Patient Characteristics
Between September 2001 and June 2003, 125 patients
were registered for S0027. Of the 117 eligible patients, 23
were ages 80 years or older. Between August 2002 and
February 2004, 111 patients were enrolled in the LUN 6 trial;
29 of these patients were ages 80 years or older. Three of the
latter patients never received treatment, and the remaining 26
are considered in this analysis. Patient characteristics of the
two 80-and-older subgroups from S0027 and LUN 6 are
displayed in Table 1. Given the similarities between these
two subpopulations in demographics, disease characteristics,
and treatment (single-agent docetaxel or vinorelbine), for the
TABLE 1. Patient Characteristics
LUN 6
(>80)
S00 27
(>80)
S00 27
(<80)
No. of patients 26 23 94
Males/females (%) 50/50 39/61 57/43
Stage IIIB/IV (%) 23/77 13/87 14/86
Performance status 0/1 or 2 (%) 80/20 70/30 64/36
Median age (yr) 81 82 73
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purposes of this report the two 80-and-older groups were
combined in reporting outcomes. In addition, the 94 patients
from S0027 who were less than 80 years old were used as a
comparative population to explore, in a preliminary fashion,
relative outcomes between patients older than and younger
than 80 years of age. Data on the under-80 group from the
LUN 6 have not yet been updated and, therefore, are not
included in this analysis. The characteristics of the under-80
population from S0027 are displayed in Table 1.
Treatment Received
Treatment was completed as planned (six cycles as
coded by the data manager) in nine patients in the 80-and-
older subgroup (39%) in S0027 compared with 43 patients in
the under-80 group (46%). The median numbers of cycles
received in the two groups were 4.5 and 5, respectively. For
the 80-and-older subgroup, the exact number of cycles could
not be determined in three patients, although they were
known to have completed fewer than six. In the 80-and-older
subgroup from LUN 6, the median numbers of cycles re-
ceived on the every-3-weeks and weekly schedules were 4
(1–10) and 3 (1–8), respectively.
Toxicity
Treatment-related toxicity (grade 3 or higher), broken
down by age and PS, is displayed in Table 2. In general,
treatment was well tolerated. Grade 3 or 4 neutropenia was
the most common toxicity, with 30% and 25% of patients
ages 80 years or older with PS of 0/1 and 2, respectively,
developing this adverse effect. In the under-80 group, grade
3/4 neutropenia was noted in 40% and 12% of patients with
PS 0/1 and 2, respectively. Significant thrombocytopenia was
rarely encountered in any patient population. Treatment-
related deaths are listed in Table 3. Two patients (4%) who
were 80 years or older, both of whom were in the every-3-
weeks docetaxel arm of LUN 6, died from treatment-related
adverse events. Three patients (3.2%) younger than 80 years
also died from treatment-related adverse events.
Response and Survival
Objective responses to treatment for patients with mea-
surable disease are displayed in Table 4. Disease control
(partial response  stable disease) was obtained in 22 (59%)
and 4 (36%) of patients ages 80 years or older with PS of 0/1
and 2, respectively. Disease control was seen in 29 (49%) and
12 (40%) of patients younger than 80 years old with PS of 0/1
and 2, respectively. Overall survival rates by age and PS are
displayed in Figures 1 and 2. For patients with good PS (0 or 1),
median and 1-year survival in the under-80 group were 11
months and 43%, respectively. In the 80-and-older group, me-
dian and 1-year survival were 7 months and 32%, respectively.
DISCUSSION
The current demographics of lung cancer reflect the
progressive aging of the general population in Western coun-
TABLE 3. Treatment-Related Deaths
>80 years old
86-year-old female, PS 1, q 3 week docetaxel, died of a cardiac arrest
after 20 days on study
80-year-old M, PS 2, q 3 week docetaxel, died of sepsis after 17 days
on study
80 years old
71-year-old female, PS 1, died of infection without neutropenia after
104 days on study
72-year-old female, PS 2, died of respiratory failure after 12 days on
study
72-year-old female, PS 2, died of respiratory failure after 26 days on
study
PS, performance status.
FIGURE 1. Overall survival by age, performance status 0 or 1.
TABLE 4. Responses among Patients with Measurable Disease
Subgroups
>80 PS 0–1 >80 PS 2 <80 PS 0–1a <80 PS 2a
(n  37) (n  11) (n  59) (n  30)
n (%) n (%) n (%) n (%)
Complete 0 0 0 0
Partial 3 (8) 1 (9) 13 (22) 3 (10)
Stable 19 (51) 3 (27) 16 (27) 9 (30)
Progression 8 (22) 4 (36) 18 (31) 11 (37)
Unevaluable 6 (16) 3 (27) 12 (20) 5 (17)
Early Death 1 (3) 0 0 2 (7)
PS, performance status.
a S0027 patients only.
TABLE 2. Toxicity (Grade 3/4)
Subgroups
>80 PS 0–1 >80 PS 2 <80 PS 0–1a <80 PS 2a
(n  37) (n  12) (n  60) (n  34)
n (%) n (%) n (%) n (%)
Anemia 2 (5) 1 (8) 3 (5) 1 (3)
Neutropenia 11 (30) 3 (25) 24 (40) 4 (12)
Thrombocytopenia 1 (3) 0 0 0
Other (grade 2–4) 28 (76) 11 (92) 55 (92) 32 (94)
Any grade 5 1 (3) 1 (3) 1 (2) 2 (6)
a S0027 patients only.
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tries. At present, two of every three patients diagnosed with
lung cancer in the United States are older than 65 years of
age, and at least one third of patients are ages 75 years or
older.2 Despite the preponderance of older patients with lung
cancer, until recently, relatively little information was avail-
able from clinical trials to provide guidance on prognosis and
appropriate management, particularly for patients with ad-
vanced-stage disease. For the 85% of patients with non-small
cell subtypes of lung cancer, we know that the current
standard of care for advanced disease is a platinum-based
doublet.17 In a subset of patients with certain clinical features,
the addition of bevacizumab further improves outcome.18
To date, no prospective phase III trial evaluating the
role of a platinum doublet has been conducted in a population
of elderly patients with advanced NSCLC. Available data
include analyses of elderly subsets from age-unspecified trials
and some prospective studies assessing the role of single
agents and nonplatinum combinations. The most commonly
employed age for defining elderly patients in these trials is an
age of 70 years or older. From the available data, a number of
conclusions can be made about the treatment of patients ages
70 years or older with advanced NSCLC: (1) the value of
single-agent therapy with drugs such as vinorelbine, gemcit-
abine, and docetaxel has been firmly established, (2) non-
platinum combinations are not clearly superior to single
agents, and (3) the role of platinum-based doublets is not
clearly defined; retrospective analyses would suggest that
they are a reasonable option for the fit elderly.
It is unclear how applicable the available data on the
use of chemotherapy in elderly patients with advanced
NSCLC are for the “very old,” who are defined as patients
ages 80 years or older. Review of the literature reveals a near
absence of data on the outcomes of chemotherapy for this
group of patients. For example, in the landmark trial ECOG
1594, which evaluated four platinum-based doublets, nine
patients (0.7%) out of the total of 1207 patients were ages 80
years or older.19 Even on elderly-specific trials, patients ages
80 years or older have represented a small minority. In the
three-arm Multicenter Italian Lung Cancer in the Elderly
Study trial, the largest prospective elderly-specific trial con-
ducted to date, patients ages 80 years or older constituted
only 3.3% (23 patients) of the total of 698 evaluable pa-
tients.12 Nevertheless, octenagarians constitute one of the
most rapidly growing segments of the NSCLC population.
More than 20% of the deaths from NSCLC will occur in
patients ages 80 years or older.1
Given the paucity of data on treatment with chemother-
apy in advanced NSCLC patients ages 80 years or older, we
thought it might be instructive to review the outcomes in the
combined 80-and-older cohorts from two recently conducted
phase II trials. Both trials had similar eligibility targeting
elderly and/or poor-PS patients, employed similar single-
agent chemotherapy regimens, and had relatively high pro-
portions of patients (21%; 49/233) ages 80 years or older with
similar patient characteristics. We also have reported the
results with the cohort of patients younger than 80 years old
from one of the phase II trials (SWOG 0027), to allow an
exploratory comparison between relative outcomes in the
older and younger patients.
A number of conclusions can be drawn from this
analysis. First, single-agent chemotherapy with either vi-
norelbine or docetaxel was relatively well tolerated. Grade 3
or 4 hematologic toxicities were the most common adverse
events encountered, but these were rarely clinically signifi-
cant, they were equally frequent in patients younger than 80
and in those 80 years and older, and treatment-related deaths
were uncommon, ranging between 3% and 4% in both age
groups. Secondly, patients with PS 2, regardless of age, fared
equally poorly. Finally, patients ages 80 years or older with
good PS had a relatively encouraging median survival of 7
months. This is comparable with the median survivals noted
for the overall populations (70 years) treated with single-
agent chemotherapy in the three Italian elderly-specific trials;
survival for those populations ranged between 4.2 and 8.3
months.10–12 The only elderly-specific phase III trial report-
ing a higher median survival was the recent phase III trial
comparing vinorelbine with docetaxel in patients ages 70
years or older, reported by the West Japan Thoracic Oncol-
ogy Group.20
Despite the encouraging survival rate of the good-PS
population ages 80 years or older, it is interesting to note that
the survival of good-PS patients ages 70 to 79 years in the
S0027 trial was still numerically better (11 months versus 7
months), raising the possibility that an age of 80 years or
older may affect outcomes independently of PS.
Clearly, this analysis suffers from a number of potential
shortcomings. As a retrospective, subset analysis, it is subject
to all of the inherent limitations of such a review. In addition,
it combines patient populations from two separate studies,
with some variation in chemotherapy regimens and patient
characteristics. Nevertheless, this report represents the largest
reported experience to date on the outcomes with chemother-
apy in a cohort of patients ages 80 years or older with
advanced NSCLC. It allows one to hypothesize that selected
patients ages 80 years or older with good PS might benefit
from single-agent chemotherapy. This analysis provides a
rationale for prospective trials of chemotherapy in patients
ages 80 years or older with advanced NSCLC.
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